NAS:MRTX (USA)
Business Description
Mirati Therapeutics Inc
NAICS : 325412
SIC : 2834
3545 Cray Court, San Diego, CA, USA, 92121
Description
Mirati Therapeutics Inc is a clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer. It operates in a single geographical segment being the United States.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 23.57 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.08 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 12.88 | |||||
Beneish M-Score | 0.56 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 49.3 | |||||
3-Year EBITDA Growth Rate | -49.2 | |||||
3-Year EPS without NRI Growth Rate | -52.1 | |||||
3-Year FCF Growth Rate | -50.1 | |||||
3-Year Book Growth Rate | 59.7 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 39.5 | |||||
9-Day RSI | 51.64 | |||||
14-Day RSI | 55.74 | |||||
6-1 Month Momentum % | -34.84 | |||||
12-1 Month Momentum % | -57.1 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 10.1 | |||||
Quick Ratio | 10.1 | |||||
Cash Ratio | 9.91 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -19.4 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -816.24 | |||||
Net Margin % | -826.41 | |||||
ROE % | -54.09 | |||||
ROA % | -46.81 | |||||
ROIC % | -575.93 | |||||
ROC (Joel Greenblatt) % | -1204.9 | |||||
ROCE % | -51.37 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 50.04 | |||||
PB Ratio | 3.76 | |||||
Price-to-Tangible-Book | 3.87 | |||||
EV-to-EBIT | -4.81 | |||||
EV-to-EBITDA | -4.82 | |||||
EV-to-Revenue | 39.18 | |||||
EV-to-Forward-Revenue | 328.25 | |||||
EV-to-FCF | -6.58 | |||||
Price-to-Net-Current-Asset-Value | 4.16 | |||||
Price-to-Net-Cash | 4.25 | |||||
Earnings Yield (Greenblatt) % | -20.85 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:MRTX
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 78.163 | ||
EPS (TTM) ($) | -11.85 | ||
Beta | 0.43 | ||
Volatility % | 98.35 | ||
14-Day RSI | 55.74 | ||
14-Day ATR ($) | 5.200938 | ||
20-Day SMA ($) | 76.125 | ||
12-1 Month Momentum % | -57.1 | ||
52-Week Range ($) | 32.96 - 195.99 | ||
Shares Outstanding (Mil) | 55.61 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Mirati Therapeutics Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |